iSTAR Tregs
iSTAR Tregs
批准号:
10731341
负责人:
MICHAEL T MCMANUS
金额:
$96.9万
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-07-01 至 2027-06-30
关键词:
AddressAggressive behaviorAntigen PresentationAntigensAutoimmuneAutoimmune DiabetesBar CodesBeta CellBiological MarkersBloodCell TherapyCellsCellular biologyClinicalDevelopmentDiabetes MellitusEffectivenessEngineeringFrequenciesHLA-A2 AntigenHomeostasisHumanImmuneImmunologyImmunosuppressionImmunotherapyIn VitroIndividualInflammationInfusion proceduresInsulin-Dependent Diabetes MellitusIslets of LangerhansKnowledgeMapsMass Spectrum AnalysisMolecularMonitorPancreasPatientsPeptidesProcessProgram DescriptionRNARegulatory T-LymphocyteResearchResearch PersonnelSafetySpecificityStructure of beta Cell of isletSurfaceT cell therapyT-Cell Immunologic SpecificityT-Lymphocyte SubsetsTCR ActivationTechnologyTestingTissuescellular engineeringearly phase clinical trialefficacy evaluationendocrine pancreas developmentexperienceextracellular vesicleshuman pluripotent stem cellhumanized mouseimmune self toleranceimprovedin vivoisletlymph nodesmouse modelnext generationperipheral bloodpreproinsulinpreservationpreventprogramsselective expressionstem cellssynergismtechnology developmenttherapeutic targettherapy development
中文摘要
摘要
英文摘要
ABSTRACT
Regulatory T cells (Tregs) are a small subset of T cells that are vital to immune self-tolerance. They
function by dominantly controlling the activities of other immune cells. In mouse models of type 1 diabetes
(T1D), a single infusion of islet-specific Tregs prevents and stably reverses autoimmune diabetes. In these
mouse models, infused Tregs accumulate in pancreatic islets and arrest autoimmune aggression against
islet beta cells by expressing immune suppressive functions locally.
Early-phase clinical trials of Treg cell therapy in patients with T1D have shown that it is feasible to produce
billions of patients’ own Tregs for infusion and the therapy is well tolerated and safe. These pioneering
efforts have paved the way for the development of next-generation Treg therapy aiming at establishing
efficacy. The research program described in this proposal focuses on a critical need for a strategy to
increase effectiveness by targeting human Tregs to the pancreatic islets and to monitor the targeting
efficacy in patients.
The proposed strategy is guided by the overarching hypothesis that shared, dominant immunopeptides
on the surface of beta cells are highly specific anchors for islet targeting. Tregs can be engineered to
target these anchors to deliver their immune regulatory function locally in the islets. Moreover, successful
engagement of Tregs with beta cells can be monitored using an engineered biomarker released into the
peripheral blood.
Aim 1 will define the immunopeptidome of pancreatic beta cells. Aim 2 will develop a cellular engineering
strategy to target Tregs efficiently and safely to pancreatic islets. Aim 3 will develop a barcode biomarker
that is released by activated Tregs into the peripheral blood. These projects together aim to develop islet-
specific TCR activation relay (iSTAR) Tregs. We have built a team of three investigators with
complementary expertise in immunology, beta cell biology, and technology development. The proposed
program synergizes our expertise to tackle the challenges in precision targeting of pancreatic islets for
the preservation of beta cell mass in T1D.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Orthogonal CRISPR GEMMs
-
批准号:10639698
-
项目类别:
-
资助金额:$66.93万
-
财政年份:2023
-
负责人:MICHAEL T MCMANUS
-
依托单位:
Illuminating gene therapy
-
批准号:10573764
-
项目类别:
-
资助金额:$20.19万
-
财政年份:2022
-
负责人:MICHAEL T MCMANUS
-
依托单位:
Functional Networks for Persister Cell Sensitivities
-
批准号:10226239
-
项目类别:
-
资助金额:$50.58万
-
财政年份:2017
-
负责人:MICHAEL T MCMANUS
-
依托单位:
Functional Networks for Persister Cell Sensitivities
-
批准号:9520153
-
项目类别:
-
资助金额:$55.18万
-
财政年份:2017
-
负责人:MICHAEL T MCMANUS
-
依托单位:
Functional Networks for Persister Cell Sensitivities
-
批准号:9383195
-
项目类别:
-
资助金额:$48.6万
-
财政年份:2017
-
负责人:MICHAEL T MCMANUS
-
依托单位:
Genetic models for exRNA communication
-
批准号:9462406
-
项目类别:
-
资助金额:$22.84万
-
财政年份:2017
-
负责人:MICHAEL T MCMANUS
-
依托单位:
Tracing Cell Lineages
-
批准号:9125766
-
项目类别:
-
资助金额:$58.49万
-
财政年份:2014
-
负责人:MICHAEL T MCMANUS
-
依托单位:
Tracing Cell Lineages
-
批准号:9336850
-
项目类别:
-
资助金额:$58.75万
-
财政年份:2014
-
负责人:MICHAEL T MCMANUS
-
依托单位:
Unlocking the Hidden Kinome
-
批准号:8898229
-
项目类别:
-
资助金额:$32.59万
-
财政年份:2014
-
负责人:MICHAEL T MCMANUS
-
依托单位:
Unlocking the Hidden Kinome
-
批准号:9114166
-
项目类别:
-
资助金额:$32.59万
-
财政年份:2014
-
负责人:MICHAEL T MCMANUS
-
依托单位:
Tracing Cell Lineages
-
批准号:8755105
-
项目类别:
-
资助金额:$39.53万
-
财政年份:2014
-
负责人:MICHAEL T MCMANUS
-
依托单位:
Unlocking the Hidden Kinome
-
批准号:8785451
-
项目类别:
-
资助金额:$32.59万
-
财政年份:2014
-
负责人:MICHAEL T MCMANUS
-
依托单位:
Genetic models for exRNA communication
-
批准号:8719063
-
项目类别:
-
资助金额:$158.9万
-
财政年份:2013
-
负责人:MICHAEL T MCMANUS
-
依托单位:
Genetic models for exRNA communication
-
批准号:9135249
-
项目类别:
-
资助金额:$168.9万
-
财政年份:2013
-
负责人:MICHAEL T MCMANUS
-
依托单位:
Genetic models for exRNA communication
-
批准号:8582079
-
项目类别:
-
资助金额:$148.32万
-
财政年份:2013
-
负责人:MICHAEL T MCMANUS
-
依托单位:
Genetic models for exRNA communication
-
批准号:8915647
-
项目类别:
-
资助金额:$164.45万
-
财政年份:2013
-
负责人:MICHAEL T MCMANUS
-
依托单位:
Resolving MicroRNA Targets
-
批准号:7587766
-
项目类别:
-
资助金额:$37.91万
-
财政年份:2009
-
负责人:MICHAEL T MCMANUS
-
依托单位:
Whole genome RNA-interference screen for novel regulators of the insulin promoter
-
批准号:7817210
-
项目类别:
-
资助金额:$49.61万
-
财政年份:2009
-
负责人:MICHAEL T MCMANUS
-
依托单位:
Resolving MicroRNA Targets
-
批准号:7851196
-
项目类别:
-
资助金额:$38.63万
-
财政年份:2009
-
负责人:MICHAEL T MCMANUS
-
依托单位:
Whole genome RNA-interference screen for novel regulators of the insulin promoter
-
批准号:7936881
-
项目类别:
-
资助金额:$49.89万
-
财政年份:2009
-
负责人:MICHAEL T MCMANUS
-
依托单位:
海外基金